Durvalumab
Last Updated: 02/24/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2516 publications
BR.31 Trial: Adjuvant Durvalumab as the Third Contender in Resected Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2026
Current Development of Perioperative Immune Checkpoint Inhibitor Therapy for Muscle-Invasive Bladder Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 19, 2026
A Case of Simultaneous Resection of Single Lung and Liver Metastases with Combined Immunotherapy after Radical Surgery for Hepatocellular Carcinoma
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
A Case of Gallbladder Cancer with Distant Metastasis with Complete Response to Gemcitabine, Cisplatin, and Durvalumab
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 17, 2026
Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 13, 2026
Erratum: Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2026
Re: Maria De Santis, Joan Palou Redorta, Hiroyuki Nishiyama, et al. Durvalumab in Combination with BCG for BCG-naive, High-risk, Non-muscle-invasive Bladder Cancer (POTOMAC): Final Analysis of a Randomised, Open-label, Phase 3 trial. Lancet 2025;406:2221-34.
Journal: European urology
Published: December 28, 2025
Up-to-Date Chemotherapy for Endometrial Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: December 24, 2025
Anti-Programmed Death-Ligand 1 Antibody-Associated Eosinophilic Granulomatosis with Polyangiitis in Non-Small Cell Lung Cancer: A Case Report.
Journal: Internal medicine (Tokyo, Japan)
Published: December 24, 2025
Utilization of extended-interval, fixed-dosing of durvalumab, every 4 weeks, in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation.
Journal: Future oncology (London, England)
Published: December 23, 2025
Correction to: Pneumonitis after chemoradiation followed by durvalumab for locally advanced lung cancer: predictors and effect on survival.
Journal: The British journal of radiology
Published: December 22, 2025
Last Updated: 02/24/2026